Devalben Patel
Overview
Explore the profile of Devalben Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stalker M, Grady C, Watts A, Hwang W, Chandrasekhara K, Sun F, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100765.
PMID: 39758601
Introduction: Osimertinib is now a standard first-line (1L) therapy for EGFR-mutated (EGFRm) advanced NSCLC. We aimed to characterize patterns of therapy and longitudinal risk of brain and liver metastasis in...
2.
Cheema P, Syed I, Gwadry-Sridhar F, Rakibuz-Zaman M, Sachdeva R, Pencz A, et al.
Curr Oncol
. 2024 Nov;
31(11):6735-6748.
PMID: 39590128
Treatment options for non-small cell lung cancer (NSCLC) are evolving, given recent and expected approvals of immune checkpoint inhibitors (ICIs) targeting programmed cell death-(ligand) 1 (PD-1/PD-L1). We retrospectively evaluated outcomes...
3.
Grady C, Hwang W, Reuss J, Iams W, Cass A, Liu G, et al.
Pharmacoepidemiol Drug Saf
. 2024 Nov;
33(12):e70049.
PMID: 39586662
Introduction: Determining lines of therapy (LOT) using real-world data is crucial to inform clinical decisions and support clinical research. Existing rules for determining LOT in patients with metastatic non-small cell...
4.
Barghout S, Meti N, Chotai S, Kim C, Patel D, Brown M, et al.
Br J Cancer
. 2024 Nov;
132(2):139-153.
PMID: 39572762
The field of precision oncology has witnessed several advances that stimulated the development of new clinical trial designs and the emergence of real-world data (RWD) as an important resource for...
5.
Haq S, Downs G, Zhan L, Schmid S, Patel D, Sacdalan D, et al.
JTO Clin Res Rep
. 2024 Nov;
5(12):100702.
PMID: 39564094
Introduction: SCLC has traditionally been considered to arise from toxic exposure factors, such as smoking. Recent evidence has revealed that germline mutations may also affect the development of SCLC; however,...
6.
Schmid S, Garcia M, Zhan L, Cheng S, Khan K, Chowdhury M, et al.
Heliyon
. 2024 Sep;
10(17):e37082.
PMID: 39296139
Background: We evaluated outcomes in non-small cell lung cancer (NSCLC) patients who presented with brain-only metastatic (BOM) disease overall and by EGFR/ALK mutation status. Methods: We analyzed clinico-demographic, treatment and...
7.
Tompkins W, Grady C, Hwang W, Chandrasekhara K, McCoach C, Sun F, et al.
JTO Clin Res Rep
. 2024 Aug;
5(8):100669.
PMID: 39157674
Introduction: Characteristics of long-term survivors in EGFR-mutant (EGFRm) NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era...
8.
Barghout S, Zhan L, Raptis S, Al-Agha F, Esfahanian N, Popovacki A, et al.
Lung Cancer
. 2024 Jul;
194:107898.
PMID: 39074423
Objectives: KRAS mutations, particularly KRAS, are prevalent in non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) have been a frontline treatment, but recently developed KRAS-selective inhibitors, such as sotorasib,...
9.
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events
Middha P, Thummalapalli R, Quandt Z, Balaratnam K, Cardenas E, Falcon C, et al.
medRxiv
. 2024 Jul;
PMID: 38947092
Introduction: Immune checkpoint inhibitors (ICIs) can yield remarkable clinical responses in subsets of patients with solid tumors but can also often lead to immune-related adverse events (irAEs). Predictive features of...
10.
Schmid S, Zhan L, Garcia M, Dietrich K, Khan K, Chowdhury M, et al.
Clin Lung Cancer
. 2024 Jun;
25(7):e277-e285.e3.
PMID: 38825405
Background: The 2018 ASCO pleural mesothelioma (PM) treatment guideline states that "a trial of expectant observation may be offered" in patients with asymptomatic inoperable epithelioid mesothelioma with low disease burden....